Author: toker

Cannabis caper ends with chase, no charges

Source link

Trump Prepares To Reschedule Cannabis To Schedule III

After weighing the “good” and the “bad,” President Donald Trump finally appears ready to direct his administration to follow through on a campaign promise to “unlock the medical uses of cannabis” as a Schedule III drug.

After holding a meeting that included cannabis industry executives on Dec. 10 in the Oval Office, Trump “is expected” to issue an executive order directing top officials in his cabinet to reclassify the plant to a less restrictive status under the Controlled Substances Act (CSA), The Washington Post reported on Thursday.

Health Secretary Robert F. Kennedy Jr. and Centers for Medicare and Medicaid Services chief Mehmet Oz also attended the meeting, while the president phoned in U.S. House Speaker Mike Johnson, R-La., who opposed the plan, arguing that several studies and data don’t support the move, the media outlet reported.

Under its current Schedule I listing alongside heroin, LSD and ecstasy as drugs with the highest potential for abuse, the federal government does not recognize cannabis as having a currently accepted medical use in the U.S. This would change under the White House’s expected plan to reschedule the plant; however, the president cannot unilaterally reschedule cannabis, and he hasn’t finalized his decision.

To Read The Rest Of This Article On Cannabis Business Times, Click Here

The post Trump Prepares To Reschedule Cannabis To Schedule III appeared first on Marijuana Retail Report – News and Information for Cannabis Retailers.

Source link

What Do Conservatives Really Think about Cannabis Behind Closed Doors? – Beyond the Official Talking Points

I decided to find out by diving into a Reddit thread on r/AskConservatives titled “Do any conservatives here oppose legalizing cannabis and why?” The responses were illuminating—not because they showed unanimous support for legalization, but because they revealed something much more interesting: genuine nuance, thoughtful debate, and perspectives shaped by lived experience rather than corporate talking points.

Source link

How to Hide the Smell of Weed Anywhere

The distinctive smell of weed is part of its charm. But we can also agree not everyone is onboard with its distinctive aroma. So, imagine you have roommates or family who don’t feel the same way about your herbal passions, how do you hide the smell of weed or get rid of the weed smell?

The post How to Hide the Smell of Weed Anywhere appeared first on Sensi Seeds.

Source link

Blackberry Herer Feminized Grow Report

This time, we’ll detail our time with Blackberry Herer Feminized. This 70% sativa leans heavily into those
genetics; these plants are extremely slender with a lanky frame and long lateral branches. While our
plant finished at a metre tall, growers could easi
ly grow them much larger. In the end, we were more
than satisfied with this strain’s impressive yield.

The post Blackberry Herer Feminized Grow Report appeared first on Sensi Seeds.

Source link

Top 3 Mint Strains

Refreshing, sweet, and ultra-potent–what’s not to love about mint strains? Find out what gives mint-flavoured cannabis its
refreshing aromas and flavours, as well as which mint strains to add to your strain wish list now.

The post Top 3 Mint Strains appeared first on Sensi Seeds.

Source link

New Hampshire Lawmakers Approve Bipartisan Bill To Legalize Psilocybin For Medical Use, While Rejecting Separate Psychedelics Measure

New Hampshire lawmakers advanced a bipartisan bill to legalize the regulated use of psilocybin for medical purposes, while rejecting a separate measure on therapeutic access to the psychedelic.

Weeks after holding an initial hearing on both proposals, the House Health, Human Services and Elderly Affairs Committee voted 18-0 on Wednesday to approve HB 1809 from Rep. Buzz Scherr (D) but 11-7 to reject HB 1796 from Rep. Michael Moffett (R).

The votes took place on the same day that members of a separate committee considered a proposal to let voters decide on legalizing marijuana on the ballot.

The psilocybin legislation that advanced, meanwhile, would create a regulatory pathway for patients with certain conditions to access the psychedelic for therapeutic use through a program overseen by the state Department of Health and Human Services (DHHS).

Moffett’s measure is more prescriptive about the proposed regulatory framework compared Scherr’s bill.

At Wednesday’s committee meeting, Rep. Yury Polozov (R) called psilocybin “an important medication, naturally occurring that can save lives.”

Rep. Lucy Weber (D) said she supported HB 1809 but not HB 1796 due to the budgetary implications of the latter proposal, calling it “fiscally imprudent.”

At the earlier committee hearing this month, Jenny O’Higgins of DHHS said officials have some concerns around the lack of appropriated funds in Moffett’s legislation, saying the department would “not be able to absorb” the program under its current budget.

Here are the key provisions of HB 1809, which advanced:

• DHHS would be responsible for approving licensed medical professional to serve as providers of psilocybin for qualifying patients.
• In order to qualify for the program, patients would need to be diagnosed with treatment-resistant depression, post-traumatic stress disorder (PTSD), substance use disorder or another condition authorized by an advisory board and DHHS.
• The legislation specifically stipulates that only natural psilocybin could be administered, excluding synthetic versions of the psychedelic.
• Providers would also need to be approved by the department to grow and harvest their own psilocybin products.
• The process for treating qualifying patients with the psychedelic would need to involve a preparation session, administration session and integration session.
• A Medical Psilocybin Advisory Board would be established, comprised of a representative of DHHS, a qualifying patient, a veterans advocate and eight medical professionals.
  • Those medical experts would need to include a psychedelics researcher, two regulators overseeing existing medical psilocybin programs and specialists in the treatment of addiction, palliative care, veterans’ affairs, naturopathy, nursing and mental health counseling.
• The board would be tasked with analyzing data on patient outcomes from DHHS, consider adding qualifying conditions for participation in the program and determine whether the law should be expanded.
• The program would only be implemented if the advisory board, within two years of the bill’s enactment, notifies lawmakers, regulators and the governor that it can be effectively administered.

“The medical community has always recognized that patients exist with serious conditions that are very resistant to effective treatment,” a statement of purpose for the measure says. “Recently, research has begun to show that certain of those patients have had positive results with the closely supervised use of psilocybin for treatment.”

“Patients with significant post-traumatic stress disorder, with treatment-resistant clinical depression, and with serious substance use disorder have been shown to benefit from the controlled, therapeutic use of psilocybin in a supervised setting,” it says. “The purpose of this act is to create a carefully monitored and closely supervised setting in which an approved medical provider can treat a carefully chosen patient with appropriate doses of psilocybin which that same provider has produced for a medical intervention.”

Here are the main details of HB 1796, which was rejected:

• The bill would permit the regulated use of psilocybin in a medically supervised setting, with DHHS responsible for overseeing the program.
• To qualify for psilocybin treatment, a patient 21 or older would need to be diagnosed with treatment-resistant depression, PTSD, substance misuse disorder, a terminal illness requiring end-of-life care or any other condition authorized by DHHS.
• A Psilocybin Licensing Board under the department would be tasked with issuing licenses for independent medical psilocybin providers, therapy providers, cultivators and testing laboratories.
• There would be specific guidelines for facilities where the psychedelic could be administered, including security requirements and other safety protocols such as ensuring there are rescue medications on site if a patient experiences an adverse event.
• The legislation would also establish a Therapeutic Psilocybin Treatment Fund, which would be funded by revenue from licensing taxes and fees. The fund would go toward studies into the possibility of expanding the program to include additional psychedelics in the program.
• The law if enacted would take effect beginning in January 1, 2027.

“The purpose of the Therapeutic Psilocybin Act is to allow the beneficial use of psilocybin in a regulated system for alleviating qualified medical conditions,” the bill’s statement of purpose says.

The prospects of either psilocybin bill advancing to enactment into law this session remain unclear, but lawmakers have been increasingly active in pursuing psychedelics reform in recent years.

Last June, the New Hampshire Senate voted to scrap compromise legislation that would have lowered the state’s criminal penalty for first-time psilocybin possession while also creating mandatory minimum sentences around fentanyl.

As originally introduced, the legislation would have completely removed penalties around obtaining, purchasing, transporting, possessing or using psilocybin, effectively legalizing it on a noncommercial basis. However a House committee amended the bill before unanimously advancing it last March.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Meanwhile in New Hampshire, the House Criminal Justice and Public Safety Committee on Wednesday took up legislation from Rep. Jonah Wheeler (D) that would put the issue of marijuana legalization before voters at the ballot this November.

The House earlier this month also approved a bill to legalize marijuana in the state—though its chances of passage in the Senate remain dubious, and the governor has expressed clear opposition to the reform.

In the Senate, meanwhile, the Judiciary Committee last week took up a bill from Sen. Donovan Fenton (D) that would allow adults over the age of 21 to legally possess up to four ounces of cannabis in plant form and 20 grams of concentrated cannabis products, as well as other products containing no more than 2,000 milligrams of THC.

Gov. Kelly Ayotte (R) has already threatened to veto any legalization bill that reaches her desk, though the constitutional amendment proposal would not require gubernatorial action.

The governor said in August that her position on the reform would not change even if the federal government moved forward with rescheduling the plant. Since then, President Donald Trump has directed the attorney general to finalize the process of moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA).

Meanwhile, the House also approved a bill this month from Rep. Wendy Thomas (D) that would allow medical marijuana dispensaries (known as “alternative treatment centers,” or ATCs, in the state) to convert their dispensary licenses to become for-profit entities. HB 54, which passed on the consent calendar with other legislation, previously advanced unanimously out of the House Finance Committee.

Part of the motivation behind the legislation is the fact that medical marijuana dispensaries don’t qualify for federal non-profit status. But in the state, they’re considered non-profit organizations, which has resulted in disproportionately increased operating costs.

Image courtesy of CostaPPR.

The post New Hampshire Lawmakers Approve Bipartisan Bill To Legalize Psilocybin For Medical Use, While Rejecting Separate Psychedelics Measure appeared first on Marijuana Moment.

Source link

Illinois Provides Another Cannabis Update – New Cannabis Ventures

Source link

Cannabis is Dangerous for Youth, So Shouldn’t We Ban it?

As cannabis becomes more widespread in society and in many ways culturally accepted, many people are keen to point out the impact on youth. While you may think that adults should be able to use cannabis if they want to or if they have a medical condition it can help with, some people forget the impact this could have on the most vulnerable people in our society.

In fact, the risks of cannabis to youth are one of the most common arguments for keeping the current approach in terms of legality.

As part of our series on the Best Arguments for and Against Cannabis, we’re taking a look at the argument that the risks of cannabis to youth are a good reason to maintain the current prohibition.

Summary: Should We Ban Cannabis Because It Is Dangerous for Youth?

Yes…

• People who use cannabis in youth are more likely to develop depression and attempt suicide. It has a negative effect on brain development.
• There is evidence that legalizing cannabis increases cannabis use disorder among youths.
• Legalizing cannabis exposes more youth to the risks, so it is not a good policy proposal.

No…

• The evidence on youth use before and after legalization is mixed – some studies also show no increase in usage rates.
• Youth use cannabis even when it is banned. In fact, having no control of the market may make it worse, since street dealers don’t check ID.
• Legalization that minimizes black market sales and ensures safe products is the best way to protect both youth and adults.  

The Risks of Cannabis to Young People

There are many potential areas of risk for young people who use cannabis. For example, there are risks associated with any smoking. However, we will focus on psychological and developmental effects on young people here. We have a post in this series addressing more general risks of cannabis if you want more information on that.

Mental health impacts of early cannabis use have been investigated by many studies. Although results can vary, when you look at all of the evidence together the picture is clear. One systematic review and meta-analysis looked at 11 studies in detail, with a total of 23,317 participants across all studies. After the authors combined the results, they found a few statistically significant differences between people who used cannabis in young adulthood vs. non-users.

People who used cannabis in young adulthood were:

• 37% more likely to develop depression
• 50% more likely to have suicidal ideation
• Almost 3.5-fold more likely to attempt suicide

This analysis did use the results for the highest-frequency cannabis users in the group. For example, if the study included once a month users and daily users, the authors took the results for the daily users. However, other research has found similar results looking at people with “non-disordered” cannabis use. This means use in the past year but without meeting the definition of cannabis use disorder.

Some studies have also found a negative impact of THC on adolescent brain development. In particular, data shows that people who started smoking cannabis in adolescence have impaired neural connectivity in regions of the brain responsible for alertness, self-conscious awareness, learning, memory, executive control, and in the subcortical networks that process habits and routines. The authors of the review write:

The impairments in brain connectivity associated with exposure to marijuana in adolescence are consistent with preclinical findings indicating that the cannabinoid system plays a prominent role in synapse formation during brain development.

Finally, there is evidence that people who start using cannabis in adolescence have an increased risk of addiction compared to those who start using later.

Legalizing Cannabis Exposes Youth to These Risks

Legalizing cannabis will make this whole situation worse if it makes youth more likely to smoke weed. There is certainly evidence of this.

Smart Approaches to Marijuana pointed out that based on the 2021/2022 National Survey on Drug Use and Health, of the 10 states with the highest past-year cannabis use at ages 12 to 17, 9 had legalized cannabis. If you look at states with the highest past-month use, 8 out of 10 had legalized.

However, it must be said that this isn’t necessarily the best way to investigate this issue. These states could have had also high youth use even before legalization. It is not clear from this “top 10” approach whether this is true. Other research has investigated this in a more comprehensive way.

One study used evidence from the same survey from 2008 to 2016. They found that cannabis use disorder increased from 2.18% to 2.72% after the legalization of recreational cannabis, a 25% greater increase than in states that didn’t legalize. Of those who’d used cannabis in the past year (in the same age group), cannabis use disorder increased from 22.8% to 27.2%.

Other research looking at young adults using the same survey also found an increase, with past-month cannabis use going from 21% to 25% after recreational legalization. A proxy measure of cannabis use disorder also showed an increase after legalization. However, in this study the increases were only detected for young adults not in college and those aged 21 to 23.

Overall, if legalization increases the likelihood youth will use cannabis, then more youth will open themselves up to the risks in the previous section.

Counterpoint: The Evidence on Legalization Increasing Youth Use is Mixed

It’s important to note the limitations of the evidence cited above. The study on young adults only found an increase in use for specific subgroups (i.e. non-college adults) and on specific measures. Notably, frequent use did not change after recreational legalization.

In the other study, the increase in cannabis use disorder risk was relatively small, and again there was no corresponding increase in other measures. For instance, both past-month use overall and frequent use among 12 to 17 year olds did not change following legalization. Many of these arguments depend on cherry-picking one or two results from papers that do not show a uniform trend.

Moreover, other research shows different results. This study used data from the Monitoring the Future survey from 2010 to 2015 to investigate the same question, looking at Colorado and Washington in particular. The results are decidedly mixed. In Washington, there was an increase in use among 8^th and 10^th graders after legalization (2% and 4.1%, respectively). But there was no difference among Washington 12^th graders and no differences at all in Colorado.

Even though it might seem obvious that legalization would increase use among youth, this is not clearly borne out by the data. The picture is actually more complicated than you might expect.

Counterpoint: Risks to Youth are a Reason to Legalize, Not Maintain Prohibition

Although the evidence on what happens to youth cannabis use after legalization is mixed, one point is unavoidable. There are no age restrictions for buying cannabis in a prohibition system, but there are in a legal system.

If we’re concerned about youth getting access to cannabis, the status quo is not something to shoot for. The dealer on the street corner is not checking IDs. Even worse, the cannabis itself has no guarantee of purity or safety. In contrast, a legal system allows age restrictions on purchases. It institutes rules to make sure that the cannabis is actually safe.

Taking steps to control the black market is crucial for this to actually work, though. States that legalize should make sure that prices are competitive (minimizing taxes at first can be very helpful) and that there are at least 10 dispensaries per 100k residents. If the black market persists, legalizing will not help keep cannabis out of the hands of youth.

Our Take: The Status Quo Already Increases Risks for Youth

While the dangers of cannabis use for youth are important and should be a factor in any discussions around legalization, most arguments on this topic ignore a key point: the current system does not protect youth.

When the black market is the only market, there are no guardrails to protect youth, there are no age restrictions, and there is no control in general. But youth still use cannabis, and so any concern about risks to youth doesn’t justify keeping the status quo.  

References

Barcott, B., & Whitney, B. (2022). ‘Opt-out’ towns are encouraging illegal marijuana sales. Leafly. https://leafly-cms-production.imgix.net/wp-content/uploads/2022/09/21143531/OptOutReport2022.pdf

About the source:

• Peer reviewed? No, a report from Leafly.
• Methodology: Used data from multiple sources to determine what percentage of cannabis sales took place in the black market vs. the state-legal market.
• Main results: States with more dispensaries per 100k residents generally capture more of the cannabis market with legal sales. “Opt-out” towns tend to reduce this number.
• Other notes: While this shows how to reduce the size of black markets, it’s important to note that there are still black markets even in “ideal” legal systems.  

Cerdá, M., Mauro, C., Hamilton, A., Levy, N. S., Santaella-Tenorio, J., Hasin, D., Wall, M. M., Keyes, K. M., & Martins, S. S. (2020). Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry, 77(2), 165. https://doi.org/10.1001/jamapsychiatry.2019.3254

About the source:

• Peer reviewed? Yes, published in JAMA Psychiatry.
• Methodology: Used data from the National Survey on Drug Use and Health from 2008 to 2016 to look at the link between recreational cannabis legalization and changes in cannabis use, frequent use and cannabis use disorder (CUD).  
• Sample size: 505,796 (149,383 aged 12 to 17).
• Main results: Past-year CUD increased from 2.18% to 2.72% among those aged 12 to 17 in states that had legalized cannabis, which was 25% higher than the increase in states that hadn’t legalized.
• Other notes:  While CUD increased in adolescents, overall use or frequent use did not, and the authors urge caution in interpreting this result.

Cerdá, M., Wall, M., Feng, T., Keyes, K. M., Sarvet, A., Schulenberg, J., O’Malley, P. M., Pacula, R. L., Galea, S., & Hasin, D. S. (2017). Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatrics, 171(2), 142. https://doi.org/10.1001/jamapediatrics.2016.3624

About the source:

• Peer reviewed? Yes, published in JAMA Pediatrics.
• Methodology: Used data from the Monitoring the Future survey to look at changes in past-month cannabis use before and after legalization in Washington and Colorado.
• Sample size: 253,902 eighth, tenth and twelfth grade students
• Main results: Cannabis use increased by 2% in eighth graders and 4.1% in tenth graders after legalization in Washington, with an overall decrease in states that did not legalize.
• Other notes:  The study found no differences in Colorado. Additionally, Monitoring the Future selects specific schools and only surveys students who attend, which may impact how much the results can be generalized.

Chen, C.-Y., Storr, C. L., & Anthony, J. C. (2009). Early-onset drug use and risk for drug dependence problems. Addictive Behaviors, 34(3), 319–322. https://doi.org/10.1016/j.addbeh.2008.10.021

About the source:

• Peer reviewed? Yes, published in Addictive Behaviors.
• Methodology: Used evidence from the National Survey on Drug Use and Health from 2000 to 2002 to investigate the risk of developing drug key signs of drug dependence for “recent onset” users at the time of the survey.
• Sample size: 5,547 recent-onset cannabis users, including 4,049 adolescents (aged under 17), as well as users of other drugs.
• Main results: Adolescent-onset cannabis users were 3 times more likely than adult-onset users to develop clinical signs of dependence.
• Other notes:  The study depends on self-reporting. However, there is no particular reason to expect it to be inaccurate.

Gobbi, G., Atkin, T., Zytynski, T., Wang, S., Askari, S., Boruff, J., Ware, M., Marmorstein, N., Cipriani, A., Dendukuri, N., & Mayo, N. (2019). Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. JAMA Psychiatry, 76(4), 426. https://doi.org/10.1001/jamapsychiatry.2018.4500

About the source:

• Peer reviewed? Yes, published in JAMA Psychiatry.
• Methodology: A systematic review of longitudinal and prospective studies looking at cannabis use before the age of 18 and the risk of developing depression as a young adult.
• Sample size: 11 studies with 23,317 individuals.
• Main results: People who used cannabis as minors were 37% more likely to develop depression, 50% more likely to have suicidal ideation and 3.46-times more likely to attempt suicide. There was no significant difference for anxiety.
• Other notes:  It is difficult to establish causality from this analysis. Some studies didn’t control for other drug use, smoking and psychosocial factors that could be linked to both depression and early cannabis use. They also point out that they didn’t know the exact amount of cannabis used or how strong it was.  

Kerr, D. C. R., Levy, N. S., Bae, H., Boustead, A. E., & Martins, S. S. (2023). Cannabis and alcohol use by U.S. young adults, 2008-2019: Changes in prevalence after recreational cannabis legalization. American Journal of Preventive Medicine. https://doi.org/10.1016/j.amepre.2023.06.009

About the source:

• Peer reviewed? Yes, published in the American Journal of Preventative Medicine.
• Methodology: Used data from the National Survey on Drug Use and Health for participants aged between 18 and 23 from 2008 to 2019. Researchers looked at frequent use, past-month use and a proxy for cannabis use disorder (CUD) for states with recreational cannabis legalization vs. those without it.
• Sample size: 123,162 college-age young adults.
• Main results: Past-month cannabis use increased from 21% to 25% and past year (proxy) CUD increased from 11% to 13% after recreational cannabis legalization. The changes were primarily seen in young adults not in college and who were 21 to 23 years old.
• Other notes:  This study only found differences after legalization for adults who would be able to legally buy cannabis. Its relevance to the overall topic here is debatable.

Sultan, R. S., Zhang, A. W., Olfson, M., Kwizera, M. H., & Levin, F. R. (2023). Nondisordered cannabis use among US adolescents. JAMA Network Open, 6(5), Article e2311294. https://doi.org/10.1001/jamanetworkopen.2023.11294

About the source:

• Peer reviewed? Yes, published in JAMA Network Open.
• Methodology: Used data from the National Survey on Drug Use and Health from youth aged 12 to 17, split into non-users of cannabis, people who used but don’t have cannabis use disorder (CUD) or people with CUD. They compared these groups for adverse psychosocial events (e.g. major depressive episodes or suicidal ideation).
• Sample size: 68,263 adolescents.
• Main results: People with non disordered cannabis use were 2 to 4 times more likely to have an adverse psychosocial event compared to non-users, and people with CUD were even more likely to have experienced one.
• Other notes:  This study was cross-sectional (at a single point in time), so it can’t show a causal relationship. The authors point out that anxiety often pre-dates substance use and the survey data doesn’t have information to let them analyze this possibility.

Volkow, N. D., Baler, R. D., Compton, W. M., & Weiss, S. R. B. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227. https://doi.org/10.1056/nejmra1402309

About the source:

• Peer reviewed? Yes, published in the New England Journal of Medicine.
• Methodology: A non-systematic review of the evidence on the adverse health effects of cannabis use.
• Main results: Long-term or heavy cannabis use has many negative effects, including addiction and increased risk of chronic psychosis disorders. Notably, it also reports a negative effect of THC on adolescent brain development.
• Other notes: This paper is likely biased in intent (i.e. listing adverse events, not “health consequences” or something neutral) and some studies it cites have been called into question. For example, a link between adolescent cannabis use and IQ declines is mentioned but this is likely due to other factors not controlled for in the original study.

The post Cannabis is Dangerous for Youth, So Shouldn’t We Ban it? appeared first on CBD Oracle.

Source link

Majority Of Virginia Voters Back Legalizing Recreational Marijuana Sales As Lawmakers Advance Bills To Do It

As Virginia lawmakers advance legislation to expand the state’s current marijuana law by legalizing and regulating recreational sales, a new poll shows that they have the support of a majority of registered voters.

Sixty percent of respondents in the survey released on Wednesday by The Wason Center at Christopher Newport University support allowing retail adult-use cannabis sales.

That includes majorities of Democrats (74 percent) and independents (59 percent), though only 38 percent of Republicans are on board.

Voters between the ages of 18 and 44 are much more likely (74 percent) to back legalizing recreational cannabis sales than are those above 45 years old (48 percent), according to the poll.

The survey results come as committees in the Virginia House of Delegates and Senate have recently approved bills to legalize and regulate the adult-use cannabis market.

While there are some differences between the chambers’ bills, the overall proposals largely align with recommendations released last month by the legislature’s Joint Commission to Oversee the Transition of the Commonwealth into a Cannabis Retail Market.

Since legalizing cannabis possession and home cultivation in 2021, Virginia lawmakers have worked to establish a commercial marijuana market—only to have those efforts consistently stalled under former Gov. Glenn

The post Majority Of Virginia Voters Back Legalizing Recreational Marijuana Sales As Lawmakers Advance Bills To Do It appeared first on GrowCola.com.

Source link